Endometrial hyperplasia. Endometrial hyperplasia
Conditions
Interventions
Intervention 1: Control group, beside receiving treatment of 40 mg Megestrol daily for 14 days of menstrual cycle for 3 months , will be treated with placebo (two pills) for12 weeks. Intervention 2:
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 72 Years
Inclusion criteria
Inclusion criteria: Endometrial hyperplasia No contraindications to treatment with metformin Creatinine clearance greater than 90ml / min Hemoglobin level above 10 Normal hepatic markers Body mass index less than 25. 18-72 years old
Exclusion criteria
Exclusion criteria: Taking metformin within the past 6 months Impaired hepatic function tests Blood sugar is less than 65 and no more than 200 History of alcohol use disorder History of vitamin B12 pregnancy History of insulin therapy Body mass index less than 25. Allergy to metformin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of endometrial hyperplasia. Timepoint: befor treatment,3 months after start treatment. Method of measurement: Review of Pathology and evaluation of uterine bleeding.;The thickness of the uterine endometrium. Timepoint: Every month for 3 times. Method of measurement: Ultrasonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of BMI. Timepoint: Before and end of the study. Method of measurement: Measure weight and height.;Comparison of blood and kidney and liver indices. Timepoint: Before and end of the study. Method of measurement: Blood sampling and measuring renal and kidney function test.;Comparison of FBS. Timepoint: Before and end of the study. Method of measurement: Blood sampling. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfsaneh Tehranian
Tehran University of Medical Sciences
Outcome results
None listed